His primary areas of study are Immunology, Immune system, Cancer research, Tumor-infiltrating lymphocytes and CD8. His Immunology study combines topics from a wide range of disciplines, such as Cytotoxic T cell and Cancer. The Cancer research study combines topics in areas such as Sunitinib, Fas ligand, Myeloid-derived Suppressor Cell and Pathology.
In his study, which falls under the umbrella issue of Sunitinib, Kidney cancer is strongly linked to Tyrosine-kinase inhibitor. His Tumor-infiltrating lymphocytes study combines topics in areas such as Interleukin 2, Cytokine, Signal transduction, T-cell receptor and CD3. His study explores the link between Tumor progression and topics such as FOXP3 that cross with problems in IL-2 receptor.
James H. Finke focuses on Immunology, Cancer research, Renal cell carcinoma, Immune system and Internal medicine. As part of one scientific family, he deals mainly with the area of Immunology, narrowing it down to issues related to the Cytotoxic T cell, and often Cytotoxicity. His Cancer research research includes themes of Peripheral blood mononuclear cell, CD8, Programmed cell death and Myeloid-derived Suppressor Cell.
His Myeloid-derived Suppressor Cell research focuses on Sunitinib and how it connects with Tyrosine-kinase inhibitor, FOXP3 and Kidney cancer. His research integrates issues of Peripheral blood, Carcinoma, IL-2 receptor and Kidney in his study of Renal cell carcinoma. James H. Finke has included themes like Tumor progression and Angiogenesis in his Immune system study.
James H. Finke mainly focuses on Myeloid-derived Suppressor Cell, Immunology, Cancer research, Immune system and Renal cell carcinoma. James H. Finke has researched Myeloid-derived Suppressor Cell in several fields, including Tumor microenvironment, T cell, Peripheral blood mononuclear cell, Sunitinib and Cystectomy. His Immunology research includes elements of Cancer, Tumor progression and Melanoma.
His research on Cancer research also deals with topics like
His primary areas of investigation include Myeloid-derived Suppressor Cell, Immunology, Cancer research, Sunitinib and Immune system. His Myeloid-derived Suppressor Cell research is multidisciplinary, incorporating elements of Bone marrow and Pathology. Much of his study explores Immunology relationship to Cancer.
His Cancer research study incorporates themes from Receptor, Autocrine signalling, Signal transduction and CD44. The Sunitinib study combines topics in areas such as Tumor microenvironment and T cell. The various areas that he examines in his Tumor microenvironment study include Sunitinib malate, Tyrosine-kinase inhibitor, Dendritic cell, Kidney cancer and Interleukin 2.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko;Arnold H. Zea;Brian I. Rini;Joanna L. Ireland.
Clinical Cancer Research (2009)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke;Brian I Rini;Joanna Ireland;Patricia Rayman.
Clinical Cancer Research (2008)
Loss of T-Cell Receptor ζ Chain and p56lck in T-Cells Infiltrating Human Renal Cell Carcinoma
James H. Finke;Arnold H. Zea;Jill Stanley;Dan L. Longo.
Cancer Research (1993)
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.
Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich.
Journal of Immunotherapy (2002)
Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
Jennifer S. Ko;Patricia Rayman;Joanna Ireland;Shadi Swaidani.
Cancer Research (2010)
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
James Finke;Jennifer Ko;Brian Rini;Pat Rayman.
International Immunopharmacology (2011)
Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma
Tomohide Tatsumi;Lisa S. Kierstead;Elena Ranieri;Elena Ranieri;Loreto Gesualdo.
Journal of Experimental Medicine (2002)
The CXC Chemokines IP-10 and Mig Are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor
Charles S. Tannenbaum;Raymond Tubbs;David Armstrong;James H. Finke.
Journal of Immunology (1998)
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
Baisakhi Raychaudhuri;Patricia Rayman;Joanna Ireland;Jennifer Ko.
Where have all the T cells gone? Mechanisms of immune evasion by tumors
James Finke;Soldano Ferrone;Alan Frey;Allan Mufson.
Immunology Today (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: